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ABSTRACT 
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The consumption of extra virgin olive oil (EVOO), a common dietary habit of 
the mediterranean people, seems to be related to a lower incidence of certain 
types of cancer including bladder neoplasm. Metastases are the major cause of 
bladder cancer-related deaths and targeting cell motility has been proposed as a 
therapeutic strategy to prevent cancer spread. This study aim to investigate the 
potential anti-metastatic and antiproliferative effect of total phenols extracted 
from EVOO against human transitional bladder carcinoma cell lines. Our 
results show that EVOO extract can significantly inhibit the proliferation and 
motility of T24 bladder cells in a dose-dependent manner. Furthermore the 
enzymatic activity of MMP-2 was inhibited at non-toxic EVOO extract doses in 
T24 cells. The qRT-PCR revealed a decrease of the MMP-2 expression, and a 
simultaneous increase of the TIMPs gene expression. The cell cycle analysis of 
two bladder cancer cell lines (T24 and 5637) after EVOO-E treatment show a 
marked growth arrest prior to mitosis in the G2/M phase for both the cell lines 
with the subsequent induction of apoptosis only in T24 cells. Finally we 
evaluated the ability of EVOOE to chemosensitize T24 to the cytotoxic action of 
common used chemoterapics. Interestingly the simultaneous treatment of 
Paclitaxel and EVOOE strongly increase the apoptotic cell death at every of the 
tested concentration if compared to the drug alone. 
 Our results may support the epidemiological evidences which link olive oil 
consumption to health benefits and may represent a starting point for the 
development of new anticancer strategies. 
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1.1 Olive oil chemical composition  
Extra virgin olive oil (EVOO) is a food produced from the first and second 
pressings of the olive fruit by the coldpressing method [1] without the use of 
chemicals, and it is composed of a glycerol fraction (which account for about 
95–99% of the olive fruit) and a non-glycerol or unsaponificable fraction (0.4–5% 
of the olive fruit) which contains phenolic compounds [2]. The saponificable 
fraction is composed mainly of triacylglycerols (triglycerides or fats) and 
contains small quantities of free fatty acids (FFA), glycerol, phosphatides, 
pigments, flavor compounds, sterols, and microscopic bits of olive. 
Triacylglycerols act as energy reserve for plants and animals. Chemically 
speaking, these are molecules derived from the natural esterification of three 
fatty acid molecules with a glycerol molecule. The fatty acids forming part of 
the triacylglycerol molecule can be saturated or unsaturated and are 
represented in the Table 1. 
The oleic acid which account for about 70-80% is the most represented 
monounsaturated lipid molecule (MUFA), followed by the polyunsaturated 
(PUFA) linoleic acid 10 % and palmitic  and stearic acid (saturated). The high 
content of MUFA and PUFA is distinctive of EVOO and is partially responsible 
for the healthy properties of this food because most of the unsaturated fatty 
acid cannot be synthesized and so are contemplate as essential dietary. Initially, 
the beneficial health effects of EVOO were attributed to the glycerol fraction 
with its high concentration of MUFAs[3]. However, several seed oils (including 
rapeseed, sunflower and soybean) containing high quantities of MUFAs are 
ineffective in beneficially altering chronic disease risk factors. Therefore, a 
substantial number of scientific works examining the biological actions of olive 
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oil phenolic compounds in the unsaponificable  fraction have been conducted. 
In recent years most of the healthy properties of EVOO are attributed to the 
polyphenolic fraction characterized by the presence of unique molecules that 
cannot be found in other biological matrix. 
1.2 Olive oil phenolics 
The total phenol content of olive oil has been reported to have a wide 
variability ranging between 100 and 800 mg/Kg. Variation in the phenolic 
profile exists among different virgin olive oils due to numerous factors, 
including the Olea cultivar and the agronomic and technological conditions of 
oil production [4, 5] The phenolic composition of EVOO is heterogeneous, with 
about 36 structurally distinct phenolic compounds identified [6]. Different 
groups of phenolic molecules can be found in virgin olive oils, such as phenolic 
acids, flavonoids,phenolic alcohols, , hydroxy-isochromans, lignans and 
secoiridoids (Figure 1).  One of the first class of phenols studied in EVOO were 
phenolic acids, this is an eterogenous combination of molecules that include 
several different acids  like gallic, protocatechuic,  p-hydroxybenzoic, vanillic, 
caffeic, syringic, p- and o-coumaric, ferulic and cinnamic . Another interesting 
family of chemical compounds found in EVOO are lignans , which include (+)-
1-acetoxypinoresinol and (+)-1-pinoresinol. These chemical compounds are 
mainly located in the woody portion of the seed and in the olive pulp and are 
released in EVOO during the extraction process.  
Flavonoids are secondary plant metabolites constituted by planar molecules 
and their structural variation comes in part from the pattern of modification by 
hydroxylation, methoxylation, prenylation, or glycosylation. During the past 
decade, an increasing number of publications on the health beneficial effects of 
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flavonoids have appeared,  such those related to cancer and coronary heart 
diseases[7-10]. 
 Phenolic alcohols are principally represented by hydroxytyrosol (HT) (3,4-
dihydroxyphenyl)ethanol (3,4-DHPEA) and tyrosol (TY )that  are identical 
except for the presence of extra hydroxyl group in the meta position. Phenolics 
alchols concentration is high variable due to different factor and is generally 
low in freshly pressed oils, but this increases during oil storage, as a 
consequence of the hydrolysis of Oleuropein (OLE). The secoiridoids belongs to 
a specific group of coumarin-like compounds, abundant in Oleaceae. This class 
of compounds  found only in the family of Olearaceae plants are well 
represented by Oleuropein which is an ester of hydroxytyrosol (3,4-DHPEA) 
and the elenolic acid (EA) glucoside (oleosidic skeleton common to the 
secoiridoid glucosides of Oleaceae). 
In latest years one of the most  studied secoiridoid was the dialdehydic form of 
deacetoxy-ligstroside aglycon better known as Oleocanthal. This particular 
molecule gain great interest after the findings of Beauchamp and coworkers [11] 
that the dialdehydic form of deacetoxy-ligstroside aglycon share a similar 
structure of the anti-inflammatory drug Ibuprofen. In this work they 
demonstrated the ability of Oleocanthal to inhibit the cyclooxygenase enzymes 
COX-1 and COX-2 and they suggested this mechanism as the key of the 
beneficial effect exerted by the  the Mediterranean diet characterized by a 
regular intake of this compound. 
 Now, after 10 years since the Beauchamp work was published a lots of 
evidences were collected  about this molecule and other EVOO phenolics 
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compound and all data seems to point out like the nutraceutical properties of 
this food are due to a synergism between them. 
1.3 Bioavailability of olive oil phenolic compounds in humans 
The knowledge of phenols metabolism after ingestion has been the subject of 
study by the scientific community due to the high intake of this molecules, 
especially in mediterranean area. Using an average total phenol content of 400 
mg/kg, and given a daily intake of 25-30ml of EVOO  an estimate of the 
amount of olive oil phenolics consumed per person each day is about 10 mg. 
[12]. Most of the studies  regarding the bioavailability of olive oil phenolics  
focused the attention on three major class of compounds: hydroxytyrosol, 
tyrosol, and oleuropein. Data obtained from different works showed  how these 
molecules are absorbed in a dose-dependent manner[13, 14]. Tuck and 
coworker[15] demonstrated, using an animal model, an increase of  
bioavailability of HT and TY of about 20% when administered as an olive oil 
solution compared to an aqueous one. They suggested that they olive oil 
matrix, due the high content of antioxidants, may protect the breakdown of 
phenolics in the g.i. tract prior to absorption The mechanism olive oil phenolic 
compounds are absorbed remains unclear, however many studies postulated 
that the different polarities of the various phenolics maybe involved in the 
absorption of these compounds[16]. Tyrosol and hydroxytyrosol are polar 
molecules and their absorption has been demonstrated to occur via passive 
diffusion[17]; unfortunately, oleuropein and ligstroside-aglycones are bigger 
and less polar than HT and currently there is no data available on their 
mechanism of absorption.  It is known that polyphenols metabolism usually 
undergo  phase I and phase II reaction, in which they are hydrolysed  and 
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conjugated into their sulphated, methylated and glucuronidated forms to be 
absorbed[18]. This process is really  important, because  polyphenols in its free 
form are undetectable or in a very low concentration  in biological matrix,  
Many studies focused their attention also on phenolics excretion.  Vissers et al 
[16]  reported a content of  hydroxytyrosol and tyrosol in urine of  about 5–16% 
of the total ingested while in a study by  Miro-Cases and colleagues[14] the rate 
of excretion of HT administered was about 24%. Further study performed by 
Visioli and colleagues[19] showed and high variability  in hydroxytyrosol and 
tyrosol excretion between 60% and 20% of the total ingested by human subjects. 
Collectively these findings  demonstrate an high variability in human 
absorption and excretion  of EVOO polyphenols probably due to individual 
differences. As most of the obtained  data is only based on three molecules, 
more investigation about bioavailability and urinary excretion of other EVOO 
bioactive molecules are needed. It’s important to notice that  the concentrations 
of EVVO phenols  in biological fluids, after their ingestion, are too low to 
explain the biological activities obtained  in vitro and in vivo models at higher 
doses/concentrations. 
 Many hypothesis have been postulated to explain discrepancies between, 
beneficial effects observed in clinical trial  related to polyphenols content of 
olive oil and their  poor bioavailability[20, 21]. Tuck et al[22] hypothesized that 
conjugated metabolites of phenols are also bioactive, they found that the 3-O-
glucuronide HT conjugate had an antioxidant activity five fold higher 
compared to hydroxytyrosol. Most of EVOO phenols pharmacokinetic  studies 
have focused the attention on some specific compounds such as TY and HT.  
Miró-Casas et al.[14] reported the presence of conjugated forms of HT in 
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plasma, this evidence is in a good agreement with other data that correlate the 
intake of EVOO with a lower oxidation status  of LDL [20, 21]. Several reports 
demonstrated that phenolic compounds and their metabolites after olive oil 
ingestion are incorporated in lipoproteins and this may explain their protecting 
antioxidant effects[20]. Globally none of these hypotheses has been fully 
corroborated experimentally.  
1.4 Antioxidant activity of EVOO phenolic compound and 
chemopreventive effect on cancer. 
The exposure to genotoxic substances of different origin (environmental or 
endogenously produced) is one of the leading causes of  carcinogenesis[23]. 
Reactive oxygen species (ROS) are continuously produced in all aerobic 
organisms and therefore constitute the most important genotoxic endogenous 
agent, this is the main reason that correlate oxidative stress with various disease 
in particularly cancer[24]. Various experiments conducted in vitro on different 
cellular model demonstrated the potent antioxidant activity of EVOO phenols 
suggesting a potential role of these chemicals in the chemopreventive ability of 
olive oil, however the protective role of EVOO phenols against DNA oxidative 
damage need to be clarified . 
Hillestrom and coworker[25] demonstrated that after the ingestion of phenol 
rich olive oil there is no significant variation in the excretion of etheno-DNA 
adducts,  moreover Machowetz et al.  established how the consumption of 
EVOO with different phenolic content cannot affect the oxidation products of 
guanine in the urine[26]. However, on other hand there are lot of work that 
support the protective role of olive oil phenols against DNA damage.  Fabiani et 
al [27] demonstrated how different phenolic compounds, obtained from olive 
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mill wastewater, can reduce H2O2 induced DNA damage in HL60 
promyelocytic leukemia cells, the same results was achieved by Warleta et al, in 
this work  HT decreases the intracellular reactive oxygen species (ROS) level in 
MCF10A cells but not in MCF7 or MDA-MB-231 cells while very high amounts 
of tyrosol is needed to decrease the ROS level in MCF10A cells[28]. Collectively 
all the data obtained from in vitro models seems to support protective role of 
phenol molecules against oxidative damage. It’s of note that  the concentration 
used in most of the scientific work previously cited is easily reachable with a 
normal intake of olive oil, at least in the enteric tract[29], taken together this 
findings suggest that EVOO phenols may prevent, in part,  the first step of 
carcinogenesis in vivo. 
1.5 Antitumor effects of olive oil phenols. 
In addition to the antioxidant activity there is a wide amount of scientific 
literature focused on exploring the antitumor potential of EVOO phenols. 
Several studies demonstrated that different molecular mechanism are involved 
in the inhibition of proliferation or induction of apoptosis; relevant data about 
the most studied tumor types are reviewed in the following section. 
1.5.1 Leukemia . 
The first study of EVOO phenols involving  a leukemia cellular model was 
conducted by Della Ragione et al [30] about fifteen years ago, they 
demonstrated that HT is able to stop cell cycle progression and inhibit 
proliferation in HL60 cell line. The observed effect was due to the release of 
cytochrome C and subsequent induction of apoptosis by Caspase 3. In this 
work they also suggest an effect phenotype-dependent because the same 
inhibition was not seen in two colorectal cancer cell line, in contrast with 
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more recent studies[31]. One of the most interesting finding of the Della 
Ragione work was that the antiproliferative effects require the presence of 
two ortho-hidroxyl groups in the phenyl ring of the molecule  since the 
treatment of the cells with TY didn’t exert any effect on cell proliferation 
similarly to what obtained in the above cited Warleta work. In the past  years 
Fabiani and coworkers has extensively studied the effect olive oil phenols in 
particular HT against different Leukemia  models[32-37], they proposed a 
“multi level” action of EVOO phenols where they modulate different 
signaling pathways involved in proliferation and apoptosis. The authors 
proposed the generation of ROS in culture media by HT as a mechanism of 
action. The oxidative stress produced by high concentration of HT trigger 
cells to apoptosis. These conclusion are supported by many evidence, since 
the removal of extracellular H2O2 by catalase induced a decrease of apoptotic 
cells in a dose dependent manner. In this work they clarify that HT can have 
a double distinct action : antioxidant at low concentration in a range of 5-15 
μM and pro-oxidant at greater concentration up to 100 μM. They observed 
an antiproliferative activity of HT, on different cell lines directly correlated to 
the amount of H2O2 in the medium. The supposed mechanism in the 
formation of H2O2 is the auto oxidation of HT by O2 and the subsequent 
formation of superoxide ions, protons and a semiquinone.  
In the light of these findings  we need to revise a lot of the results obtained 
from in vitro experiments that don’t take in account hydrogen peroxide 
production. This finding provide a new perspective in the study of this kind 
of molecules. 
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1.5.2 Colorectal cancer  
Dietary habits has been  strictly associated with colorectal cancer (CRC) risk 
and Mediterranean countries shows lower prevalence of this neoplasm if 
compared with other western countries. One of the hallmark of the 
Mediterranean diet (MD) is the high consumption of olive oil and this   could 
be a key factor in reducing the onset of CRC. Hashim et al[38, 39] 
demonstrated that EVOO phenols can inhibit proliferation of colon cancer 
cells both in vitro and in vivo using different experimental approach. One of 
the mechanism of action proposed by Guichard and coworkers [40], to 
explain the block of the proliferation by tyrosol on HT29 cells, involve the 
extracellular signal-regulated kinase (ERK) 1/2  and Akt/PKB pro-survival 
factors by altering their phosphorylation status. The same results was 
achieved by Corona et al [41], using Caco-2 cells they found a rapid 
inhibition of ERK 1/2 phosphorylation and a subsequent reduction of cyclin 
D1 and COX-2 expression. Cardeno et al investigated the relation between 
(hypoxia inducible factor) on HT29 cells. After 24 hours of exposure OLE 
upregulation of P53 protein espression[42]. In more recent years the work of 
Di Francesco et al[43] evaluated the epigenetic change behind the exposure 
of colorectal cancer cells to  HT. Interestingly they found an up regulation of 
 CNR1 gene — encoding for type 1 cannabinoid receptor (CB1) which is 
known as a tumor suppressor gene. After exposing the cells to EVOO phenol 
extract or HT they found a reduced CpG methylation of the promoter of 
CNR1 gene consistent with the antiproliferative effect seen. In the same work 
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similar epigenetic alteration were observed in vivo  in the colon of rats fed for 
10 days with EVOO supplementation. It’s of great interest to note  that many 
of the study conducted on colorectal cancer were made using an in vivo 
experimental model and as above mentioned the obtained data were 
comparable to those obtained in vitro, thus highlighting the potential role of 
this class of compound in the prevention of this kind of neoplasm. 
1.5.3 Breast cancer 
The incidence of breast cancer (BC) in the Mediterranean area is much lower 
if compared to all the world and it is the main reasons for the growing body 
of scientific literature about the relation between BC and nutraceuticals[44, 
45]. One of the first evidence of the antiproliferative properties of EVOO 
phenols against a BC cellular model was obtained by Han et al[46] in this 
work they demonstrated that Oleuropein and Hidroxytirosol were able to 
block cell cycle progression at G1 stage in MCF7 breast cancer cell, with a 
subsequent apoptosis activation. Interesting several studies investigated the 
ability of EVOO phenols to interfere with ER signaling[47-53], it’s well 
known that estrogens promote the proliferation of ER-positive breast cancer, 
therefore the ER receptor could be an important pharmacological target in 
this disease. The aromatic ring contained in OLE and HT could compete with 
the estrogens (which share similar structure) for the estrogen receptor 
binding sites, this is a common feature of other phytoestrogen like quercetin 
and genestein. Other than canonical activation of ER signaling Sirianni et 
al[54] demonstrated that OLE and HT could block BC cell proliferation 
trough the inhibition of ERK1/2 activation. In a recent study Akl et al[55] 
investigated the intracellular mechanism responsible of the antiproliferative 
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effect of Oleocanthal against a BC experimental model. The treatment of 
three different BC cell lines produced a  dose-dependent inhibition of HGF-
induced cell migration, invasion and a block of cell cycle progression in the 
G1/S phase. Moreover, They found that (-)-oleocanthal treatment effects 
were  mediated via inhibition of HGF-induced c-Met activation and its 
downstream mitogenic signaling pathways with a subsequent block of EMT 
and reduction in cellular motility. In this work they also showed an 
inhibition of tumor growth in an orthotopic model of breast cancer in 
athymic nude mice after treatment with (-)-oleocanthal.  
Despite the large amount of scientific work investigating the role of EVOO 
polyphenols in various tumor model, surprisingly there are no literature data 
about the interaction between these molecules and  bladder  neoplasia. 
1.6 Bladder cancer and nutrition: is there a relationship? 
Bladder cancer (BCa) is one of the most common cancer in Western countries 
and the first  cause of death among urinary malignancies. BCa incidence and 
mortality rates vary substantially across countries due in part to different risk 
factors. In 2007, a comprehensive review by the World Cancer Research Fund 
and the American Institute for Cancer Research concluded that established risk 
factors for bladder cancer include tobacco consumption, infection with 
Schistosoma haematobium, and both occupational and environmental 
exposures to carcinogens such as aromatic amines and polycyclic aromatic 
hydrocarbons and arsenic in drinking water[56]. The role of nutraceuticals like 
protecting factor in the developing of BCa remain still unclear but there are 
many data that seems to link a regular consumption of fruit and vegetables 
with a lower incidence of urothelial neoplasia. A recent study in the multiethnic 
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cohort showed how the intake of vegetables and some related micronutrients 
such as vitamins A, C, E and carotenoids were inversely associated with 
bladder cancer risk only in women[57]. Ros et al found an association between 
higher plasma carotenoids concentrations and a lower incidence of bladder 
cancer  suggesting that specific compounds in fruit and vegetables may have 
protective a protective role towards bladder cancer carcinogenesis[58]. 
Moreover, data of the European Prospective Investigation into Cancer and 
Nutrition (EPIC) study, found an inverse association between  the dietary 
intake of flavanols and lignans and the risk of bladder cancer[7]. Despite the 
above mentioned data, collectively, there is a lack of clear epidemiological 
evidence that link consumption of polyphenols reach food and BCa, even if is 
well know that these molecules are excreted trough urine in a dose dependent 
manner[59]. Dietary studies are commonly limited in their conclusions because 
of heterogeneity of the population studied, variations in lifestyles and the 
complexity of diet, with different components of the food exerting potential 
chemopreventive effects, but also containing carcinogens derived from 
environmental pollution. However, the weak epidemiological evidences 
indicating a protective role of the diet phytochemicals against BCa are well 
supported by different biological findings. It was demonstrated that the urine 
of the BCa patients exhibit high levels of 8-hydroxydeoxyguanosine which is a 
marker of oxidative stress excreted in urine upon DNA repair, in this work the 
authors concluded that genotoxic damage induced by oxidative stress may be 
an important pathological feature of bladder cancer patients[60].This finding is 
of great interests if taken together with the above mentioned Tuck et al work  
that demonstrated how the conjugate form of EVOO phenols excreted in urine 
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retain all of the antioxidant properties of the ingested compounds. Collectively 
the above reviewed data seems to support the thesis that polyphenols rich food 
like can act like a protecting factor against BCa but more investigation about 
bioavailability and urinary excretion of these bioactive molecules are needed. 
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2 Aims 
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2.1 To nvestigate the ability of EVOO phenols to modulate 
biological process related to bladder cancer cell motility  
 
The consumption of extra virgin olive oil (EVOO), a common dietary habit of 
the mediterranean people, seems to be related to a lower incidence of certain 
types of cancer including bladder neoplasm[61]. Metastases are the major cause 
of bladder cancer-related deaths and targeting cell motility has been proposed 
as a therapeutic strategy to prevent cancer spread[62]. The first part of this  
study aim at  investigate the potential anti-metastatic effect of total phenols 
extracted from EVOO against the human transitional bladder carcinoma cell 
line T24 using an in vitro approach.  
2.2 To investigate the  antiproliferative activity of EVOO phenols 
and its ability to chemosensitize bladder cancer cells to 
chemotherapics. 
 
In the second part we will focus our attention on investigating the 
antiproliferative activity of EVOO-E and its ability to improve the cytotoxic 
properties of commonly used chemoterapics in the same experimental 
condition described above (2.1).  
Even if the correlation between bladder cancer and diet  has been a topic of 
interest of many epidemiological studies, most of them were focused on the role 
of nutraceutical as a possible chemopreventive   for this  disease. To date there 
is a small amount of  research about  the role that nutraceutical can play once 
the cancer is identified. The data about the interaction between antioxidant of 
vegetal origin and chemotherapy are controversial and opposing[63-65].  In our 
opinion this topic is really important as patients are increasingly searching for 
ways to improve in a safe manner the common pharmacological approach.  
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3 Materials and methods
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3.1 Extraction of the phenolic fraction. 
EVOO-E were obtained according to previously published methods [66] with 
some modification, from 30 different lots of an endemic monocultivar olive oil 
(Olea europaea L. var. Itrana) within one month after production. Fifty milliliters 
of each oil sample were extracted with 150 mL of CH3CN/H2O (70:30 v/v) 
(Sigma–Aldrich, St. Louis, MO, USA). A defatting with n-hexane was 
performed to completely remove the lipid fraction. Aliquots of the raw 
hydrophilic extract were dried by speedvac and stored at -80°C until use. The 
extract was redissolved in DMSO (Sigma–Aldrich, St. Louis, MO, USA) at a 
stock concentration of 10 mg/mL immediately before performing experiments. 
3.2 HPLC analysis of the EVOO extract. 
The HPLC analysis of the extract was carried out with a Waters apparatus, 
equipped with a 600 F pump and pump controller models, a Rheodyne 
injection valve with a 50 μl loop, a Symmetry 300 column (C18 reverse phase, 
4.6x250 mm, 5 μm particle size, thermostated at 25°C, with a 3.9x20 mm guard 
column of the same material matrix) and a Waters 2996 Photodiode array 
detector. The elution was performed at a flow rate of 1 mL/min, with solvent A 
being 2% acetic acid and solvent B being methanol. The gradient consisted of an 
initial 5% B for 5 min, to 50% B in 35 min, 100% B in 10 min, 100% B for 10 min.  
Samples were filtered through a 0.45 μm cellulose syringe filter before injection. 
Elution was monitored at 280 nm and peak identification was obtained by 
comparing retention times and spectral characteristics with those of authentic 
standards. 
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3.3 Cell cultures. 
T-24 ,5637 cells (human urinary bladder carcinoma) were obtained from Cell 
Lines Service (CLS, Eppelheim, Germany)  and cultured in DMEM medium 
supplemented with 10% FBS, 2 mM glutamine, 100 units/mL penicillin and 100 
µg/mL streptomycin. All media and sera for cell culture were purchased from 
Gibco (Grand Island, NY, USA) and were endotoxin-free. Human urothelial 
fibroblast were collected according to previously published methods [67]  and  
kindly provided by Dr. Elena De Falco (Department of Medical-surgical 
Sciences and Biotechnologies, “Sapienza” University of Rome) and cultured as 
above described for T24 cells. HT1197 were obtained from ICLC  (ICLC, 
Genova, Italy)  and cultured in MEM medium supplemented with 10% FBS, 2 
mM glutamine, 100 units/mL penicillin and 100 µg/mL streptomycin 
3.4 Cytotoxicity assays. 
Cell viability was assessed by Trypan blue (Sigma–Aldrich, St. Louis, MO, 
USA) exclusion assay and  using the dye [4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) (Promega Corporation, Madison, WI). The 
assay is based on the ability of living cells to convert MTT into an insoluble 
purple-coloured formazan, whose amount is proportional to the number of 
living cells. Cells seeded in 96-well plates at a density of 5000 cells/well were 
exposed to EVOO-E at a concentration ranging between 2.5 and 100 μg/mL. 
After 24 hours, cells were treated with 20 µl of a 5 mg/mL solution of MTT in 
phosphate buffered saline (Gibco, Grand Island, NY, USA) and incubated at 
37°C for 4 hours. After discarding the medium, the formazan was extracted 
with DMSO, and absorbance read at 570 nm with a reference at 690 nm. 
29 
 
3.5 Colony forming ability 
The cells were plated at  density of  200 per 10-cm dishes and exposed to 
various concentration of EVOO-E. Cells were grown for 14 days with a media 
renewal every two days. After two weeks  the cells  were  fixed with ethanol, 
and stained with Giemsa to detect colonies. 
3.6 Cell adhesion assay. 
Cell adhesion assay was performed as previously described [68]. Briefly, the 
cells (1 × 105/well) were resuspended in culture medium containing different 
concentrations of EVOO-E and were plated into 96-well plates coated with 
fibronectin (Becton–Dickinson, Bedford, MA). After incubation in 5% CO2 at 
37°C for 6 hours, the cells were washed thrice with PBS to remove the non-
adherent cells. The attached cells were analyzed by MTT assay. 
3.7 Migration assay. 
The migration assay was performed through the chemotactic directional 
migration by using a 24-well transwell insert (8 μm pore size, EMD Millipore, 
Temecula, CA, USA). The cells (104 cells/well in serum free DMEM) were 
placed in the upper chamber and treated in the absence or in the presence of 
EVOO-E (2.5, 5 and 10 μg/mL) while the lower chamber was filled with DMEM 
supplemented with 10% FBS as a chemoattractant. After 24 hours of incubation, 
a cotton swab was used to remove the non-migrated cells in the upper chamber 
then the filters were individually stained with 2% crystal violet and the 
migrated cells adherent to the underside of the filter were examined, counted 
and photographed under a microscope at x200 magnification. 
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3.8 Invasion assay. 
The invasion assay was performed by using Matrigel (BD Biosciences, Bedford, 
MA, USA)-coated transwell cell culture chambers (8 μm pore size, EMD 
Millipore, Temecula, CA, USA) as described previously. The cells (104 cells/0.4 
mL) were cultured for 24 hours in serum-free DMEM medium and then placed 
in the upper chamber of the transwell insert (5x104 cells/well) and treated with 
0, 2.5, 5 and 10 µg/mL of EVOO-E. The lower chamber was filled with DMEM 
supplemented with 10% of FBS and the corresponding concentration of extract 
used in the upper side. The cells were incubated for 24 hours at 37°C in a 
humidified atmosphere with 95% air and 5% CO2. At the end of incubation, 
cells were stained as above described. 
3.9 Gelatin zymography. 
The activities of MMP-2 and MMP-9 were measured after exposure to various 
concentrations of EVOO-E. The cells (4x105 cells/well) were plated in 6-well 
tissue culture plates and incubated in DMEM supplemented with 10% of 
serum. Before reaching 80% of confluence the cells were washed twice with PBS 
and incubated in serum free medium with or without 2.5, and 10 μg/mL of 
extract for 24 hours. An appropriate volume of conditioned medium, adjusted 
for vital cell number [69], was loaded on a 9% sodium dodecyl sulfate-
polyacrylamide gel under non-reducing conditions. After electrophoresis, the 
gel was soaked in 2.5% Triton X-100 (Sigma–Aldrich, St. Louis, MO, USA) twice 
for a total of 60 min at 25°C, then it was incubated in substrate buffer (50 mM 
Tris, pH 7.6, 10 mM CaCl2, 50 mM NaCl and 1μM ZnCl2) at 37°C for 18 hours. 
Positive controls were achieved using recombinant human MMP-2 and MMP-9 
(Calbiochem, San Diego, CA, USA). Bands corresponding to activity of MMP-2 
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and -9 were visualized by negative staining using 0.3% Coomassie Brilliant Blue 
in 50% methanol and 10% acetic acid as described elsewhere [69]. 
Quantification of the data from the band density was performed by NIH ImageJ 
software. 
3.10 Quantitative real-time PCR of  EMT  gene expression. 
Cells (1 × 106 cells/well) were placed in 6-well plates and incubated with 
various concentrations of EVOO-E. Cells were collected and total RNA was 
extracted from each treatment as previously described. RNA samples were 
reverse-transcribed at 42°C with High Capacity cDNA Reverse Transcription 
Kit for 30 min according to the protocol of the supplier (Applied Biosystems, 
Foster City, CA, USA). Oligonucleotide primers sequences used were listed in  
Table 2. 
Applied Biosystems 7500 Real-Time PCR system was used for each assay in 
triplicate and expression fold-changes were derived using the comparative CT 
(threshold cycle) method [70, 71] using 18S as reference gene. 
3.11 Cell cycle analysis 
Briefly  cells were harvested and seeded into 25 cm2 flasks at a density of 3 × 
105 cells 48 hr before treatment with olive oil phenolic extract at various 
concentrations (0, 10, 20, 40 μg/ml) in triplicate. Media containing the olive oil 
phenolic extract was added and the cells incubated for 24 hr at 37°C/5% CO2. 
Cells were then washed with PBS and harvested by the addition of 1 ml trypsin 
EDTA and incubation at 37°C for up to 5 min. Two millilitres of serum-
containing medium was added to inactivate the trypsin. At this stage, a cell and 
viability count was carried out using a haemocytometer and trypan blue dye. 
The cells were transferred to polypropylene tubes (Becton Dickinson) and 
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centrifuged at 258g for 3 min. The supernatant was carefully discarded and the 
pellet re-suspended in 200 μl of ice cold PBS and 2 ml of 70% ethanol/30% PBS. 
Cells were incubated on ice for 30 min, centrifuged at 258g for 3 min, the 
supernatant carefully discarded, and the cells re-suspended in 800 μl of ice cold 
PBS, 100 μl of RNase A (1 mg/ml) (Sigma Chemicals), and 100 μl of propidium 
iodide (400 μg/ml) (Sigma Chemicals). The cells were then incubated at 37°C 
for 30 min before being analysed. Samples were processed on a Accuri C6 flow 
cytometer (Becton Dickinson Immunocytometry Systems, UK)  equipped with a 
laser (excitation wave length = 488 nm), and the fluorescence emission spectra 
of propidium iodide was collected at 585 nm (designated FL2), using C6 
Software (Becton Dickinson). A total of 10,000 events were captured. These 
emission spectra were analysed subsequently for DNA content using ModFit 
LT Software (Verity Software House, Topsham, ME). Each experiment was run 
in duplicate and the complete data set is the mean of 3 independent 
experiments. The complete dataset was analysed using ANOVA carried out in 
SPSS for Windows. 
3.12 Immunofluorescent staining of F-actin and β-Tubulin. 
 
For immunofluorescent labeling, after EVOOE treatment cells were 
simultaneously fixed and permeabilized by brief (1 min) treatment with 0.25% 
Triton X-100 and 0.5% paraformaldehyde in cytoskeleton buffer (10 mM MES, 
150 mM NaCl, 5 mM EGTA, 5 mM MgCl2, and 5 mM glucose, pH 6.1) and then 
postfixed with 1% paraformaldehyde for 10 min, washed with PBS, and 
reduced in 1 mM sodium borohydride, to reduce autofluorescence. Coverslips 
were then incubated for 40 min with 10 μl of 1:200 diluted primary mouse 
antiβ-Tubulin antibody droplets, or with 1:200 TRITC-conjugated phalloidin 
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(Cell Signaling Technology). The sample preincubated with primary antibody 
where washed three times with PBS, and incubated with the secondary goat 
anti mouse FITC conjugated  antibodies for 40 min. After an additional three 
washes with PBS, the nucleus were counterstained with DAPI and  the 
coverslips were mounted on glass slides in Elvanol (Mowiol 4-88, Hoechst, 
Frankfurt, Germany). 
3.13 Western blot analysis  
The  cells (2 × 106) were seeded in a six-well plate. After 24hours, cells were 
treated with different concentrations of EVOO extract for 24. Cells and culture 
medium were then harvested, washed twice with PBS, and finally lysed into 
RIPA buffer (50 mM Tris, pH 8, 150 mM NaCl, 1% NP40, 0.5% Na-
deoxycholate, and 0.1% sodium dodecyl sulfate; SDS), containing a protease-
inhibitor . After 20 minutes on ice, lysates were centrifuged at 20,000 × g for 10 
minutes. Protein concentration was determined with the Bradford method. The 
lysates (20 μg of the total protein) were resolved on 8-12% SDS-PAGE 
(polyacrylamide gel electrophoresis) and transferred onto PVDF  membranes. 
Membranes were blocked for 1 hour with 5% (BSA), dissolved in TBS solution 
(10 mM Tris-HCl, pH 7.5, 150 mM NaCl). Membranes were then successively 
incubated overnight at 4°C with the following primary antibodies: rabbit 
polyclonal anti-PARP diluted 1:2000 in TBST (TBS with 0.1% Tween 20) with 
5% BSA and mouse procaspase 3 and rabbit procaspase 9 diluted 1:500 in TBST. 
After washing in TBST solution, the secondary antibody ( antirabbit  -mouse 
IgG horseradish peroxidase (HRP)-conjugated antibodies Cell Signaling 
Technology), diluted in TBST/5% BSA, was added for 50 minutes at room 
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temperature. signals were visualized by ECL reagent  according to the 
manufacture instructions. 
3.14 Statistics. 
Each assay was replicated at least four times, and statistical significance was 
determined using Graphpad Prism 4 statistical software package (Graphpad, 
San Diego, CA, USA). Data were expressed as mean ± SEM. Comparison of the 
groups was made by one-way ANOVA followed by Bonferroni’s post hoc test. 
Statistical significance was defined as P < 0.05. 
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4 RESULTS AND DISCUSSION
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4.1 EVOO-E chromatographic analysis.  
After the extraction process from the different EVOO samples we  performed 
identification of the main phenolic compounds in EVOOE by HPLC-DAD. 
Chromatographic analyses   revealed no major differences in phenolic content 
of the various lots ( see Table 3)  which were characterized by a large amount of 
secoiridoids such as dialdehydic form of elenolic acid linked to tyrosol (p-
HPEA-EDA) and dialdehydic form of elenolic acid linked to hydroxytyrosol 
(3,4-DHPEA-EDA), and of lignans such as pinoresinol. As regards the 
remaining compounds, TY and HT were the most abundant, whereas the 
remain was represented by simple phenolics such as  vanillic acid, vanillin,  p-
coumaric acid, ferulic acid. For our aims we extracted the phenolic fraction 
from thirty different lots of an endemic monocultivar olive oil (Olea europaea L. 
var. Itrana) within one month after production in order to obtain a EVOO 
fraction rich in complex phenols. These results are in good agreement with 
literature data which report chromatographic profiles strictly similar to what 
obtained in our experimental conditions [72-74]. Furthermore, it is noteworthy 
that the different lots of olive oil analyzed present a low content of simple 
phenols such as TY and HT (Figure 3). These two compounds typically derive 
from the degradation of more complex molecules, such as secoiridoids and 
lignans, during prolonged storage or due to sub-optimal extraction conditions 
to limit simple phenols TY and HT (high temperature, crushing, malaxation, 
prolonged contact with waste waters, etc…) [75]. Hence our data indicate that 
the analyzed samples were obtained by correct production procedures giving 
rise to a high quality EVOO. 
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4.2 EVOO-E inhibits T24 migration and invasion 
Prior to perform cell motility related experiment  we evaluated the effect of 
different concentrations of EVOO-E on cell viability. In our experimental 
conditions EVOO-E was found to affect T24 cell viability after 24 hours of 
treatment at concentrations greater than 10 µg/mL in a dose dependent-manner 
(Figure 4). Notably, at the same concentrations fibroblasts viability was not 
affected. Despite their different histologic origin than T24  we decided to use 
fibroblast as a non–cancer control because of their marked motility. These 
results suggested that EVOOE selectively affects urothelial cancer cells, thus 
indicating that the cytotoxic potential is not attributable to an unspecific   effect 
when compared to the control both in T24 and in fibroblasts. As regards cell 
migration and invasion, data indicate that fibroblasts were not inhibited by the 
phenolic extract at the tested concentrations (Figure 4). Contrary to what 
observed for fibroblasts, the migration assay showed that the phenolic extract 
had a significant inhibitory effect on T24 cell motility. After 24 hours of 
treatment with the same doses of EVOO-E used above the percent of migrated 
cells decrease from 70 ± 2% to 10 ± 3%, respectively (Figure 4). Furthermore, the 
penetration of the Matrigel-coated filter by T24 cells was substantially inhibited 
in the presence of EVOO-E in a dose dependent manner. The percent of 
invading cells after exposure to EVOO-E concentration ranging between 2.5 to 
10 μg/mL drastically decrease from 53 ± 2% to 12 ± 1% respectively (Figure 4). 
It is of note, the observed inhibition occur at subtoxic doses of EVOO-E as 
shown by viability experiments. 
Figure 5 reports the invasion index, which is the ratio between the number of 
invading cells and the number of migrating cells in the same experimental 
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conditions, and allows to determine which is the reciprocal contribution of the 
two phenomena [76]. The statistical analysis of the data showed a significant 
difference between T24 migrating and invading cells (P<0.001) at EVOO-E 
concentration of 2.5 and 5 μg/mL (Figure 5). Data indicate that at 2.5 and 5 
μg/mL of EVOO-E the percent of migrating vs invading T24 cells was 
significantly different than untreated (P<0.001), with an invasion index of 0.72 
and 0.67, respectively. 
4.3 EVOO extract attenuates the enzymatic activities of MMP-2 in T24 cells 
Due to the observed biological effects exerted towards cell motility we decided 
to focus our attention on evaluating the activity of two proteins mainly 
involved in cell motility process. The matrix metalloproteinases MMP-2 and -9, 
also known as the gelatinases, have been long recognized as major contributors 
to the proteolytic degradation of extracellular matrix during tumor invasion. In 
order to determine the effect of EVOO-E on the proteolytic activity, we 
investigated whether the extract could affect the secretion of gelatinases.  
After 18 hours  of treatment, the conditioned media of cells grown in the 
presence or absence of EVOOE were subjected to gelatin zymography to 
analyze MMP-2 and MMP-9 activities. Matrix metalloproteinases (MMPs), a 
family of Zn2+-dependent endogenous proteases, are able to degrade various 
components of the extracellular matrix. In the extracellular domain, the activity 
of these proteases is tightly regulated by inhibitors known as tissue inhibitors of 
metalloproteinases (TIMPs). It has been postulated that TIMPs act as tumor 
suppressor genes due to their anti-metalloproteinase activity and their 
protective role on the extracellular matrix [77]. The imbalance between MMPs 
and TIMPs may be an indicator for cancer prognosis [78]. Most data published 
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on MMP-2 and MMP-9 seem to link their role to aggressive behavior of 
different cancer types (Table 4). Indeed, MMP-2 overexpression is found to 
correlate with poor survival in different type of cancers [79-82]. The results 
shown in Figure 7 indicate that EVOOE significantly reduced only MMP-2 
activity in a dose-dependent manner, with an inhibition of about 48% at 2.5 
μg/mL and of 90% at 10 μg/mL (P <0,001). Moreover the exposure to EVOO-E 
did not affect the MMPs activities in fibroblasts conditioned medium, with no 
significant differences between control and treated samples. Indeed, enzymatic 
activity analysis reveals a significant decrease specifically for MMP-2 
expression. 
4.4 EVOOE alters the levels of gene expression associated with EMT  only in 
T24 cells. 
To better understand the molecular events behind the alteration of cell motility 
we decided to perform qRT-PCR of  genes related to EMT. The epithelial-
mesenchymal transition (EMT) is a multistep process in which epithelial cells 
lose their epithelial phenotype and acquire mesenchymal characteristics, such 
as motility and invasive properties. Numerous in vitro and in vivo studies 
suggest that the EMT is associated with cancer cell invasion and metastasis in 
various malignancies, including bladder cancer[83]. Despite their epithelial 
origin,  T24 cells are a useful tool to assess a possible reversion of EMT due to 
the high expression level of mesenchymal genes such as MMP2, N-Cadherin, 
and β-Catenin. As shown in Figure 6, EVOO-E induced a tenfold reduction of 
MMP-2 gene expression in T24 cells at both concentrations without affecting 
MMP-9 mRNA expression (Figure 6). Moreover the treatment with subtoxic 
doses of EVOOE also induced a strong down regulation of Vimentin and β-
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Catenin.  In the same experimental conditions we also observed a significant 
increase of the levels of TIMP-1 and TIMP-2. The treatment of fibroblasts with 
EVOO-E did not gene expression levels at the tested concentrations (Figure 6 ). 
The above data show an upregulation of TIMP-1 and TIMP-2 which are 
endogenous tissue inhibitors of metalloproteinases. TIMP-1 has been shown to 
regulate MMP-2 activity and numerous evidences have indicated a correlation 
between elevated TIMP-1 levels and diminished MMP-2 activity and cell 
invasiveness[84-86]. These inhibitory effects of EVOO-E on T24 cells are not due 
to the cytotoxic effect of polyphenols because the viability of these cancer cells 
was not affected in the range of  concentration tested (Figure 4).  
We also evaluate the gene expression levels of cadherins. E-Cadherin is 
considered an active suppressor of invasion and growth of many epithelial 
cells. Recent studies indicate that cancer cells have up-regulated N-Cadherin in 
addition to loss of E-Cadherin, this change is called “cadherin switch” and is 
one of the hallmark of EMT[87]. The data obtained showed a marked decrease 
in the level of N-Cadherin gene expression with a subsequent up-regulation of 
E-Cadherin after the treatment with EVOO-E. Taken together all the data 
collected with qRT-PCR demonstrated how the treatment with EVOO-E is able 
to revert EMT restoring a less invasive phenotype in T24 bladder cancer cells. 
Interestingly the gene expression analysis revealed also a strong down-
regulation of β-catenin expression   which  is a transcription factor of the Wnt 
signaling pathway and is involved in the regulation of cell adhesion.  
Furthermore these data indicate that EVOO-E mechanism of action is in part 
due to a regulation of gene expression, particularly for those proteins involved 
in migration and invasion. 
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4.5 EVOOE inhibits cell growth and clonogenical survival in a 
dose dependent manner . 
In the second section of this study we decided to evaluate the ability of EVOOE 
to inhibit cell proliferation, for this purpose we added other two bladder cancer 
cell lines to our experimental model. Initially the  effect of EVOOE on cell 
viability was assessed by trypan blue exclusion assay and the obtained dose 
response curves are shown in Figure 8. After 24 hours of exposure to various 
amount of extract, T24 cell viability was not affected at concentrations up to 10 
µg/mL whereas it decreased in a dose dependent manner at higher 
concentrations with an IC50 of 32 ± 3 µg/mL. 
The viability of 5637 cells was  also inhibited in a dose depend manner with an 
IC50 of 55 ± 7 µg/mL.  On the contrary HT1197  viability was only slightly 
affected at highest concentration of EVOOE. Human primary fibroblasts 
viability seems to be not altered by the cytotoxic properties of the phenols 
extract.  The different susceptibility to polyphenols extract among the tested 
cells is probably ascribable to  different biological factors such as gene 
mutational status. After this set of experiments we decided to exclude the 
HT1197 from  next experiments due to the high concentration of EVOOE 
needed  ( more than 100 µg/mL) to block cell proliferation. Even if  there is a 
wide amount of  scientific literature  that  studied cytotoxic effect of extracts of 
various origin at very high concentration, we decided to perform our 
experiments using a  rather low concentration of  EVOOE, more representative 
of what can be  reached in vivo with a phenol rich MD.   
After this first set of experiments we also decided to compare the cytotoxic 
properties of three selected components of the phenolic mixture versus the 
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whole extract (EVOOE), the obtained dose response curves are shown in the 
figure 8. As expected, despite identification of several active chemical 
compounds in EVOOE, none of the isolated polyphenols demonstrated a 
biological activity higher than the whole oil extract (Figure 8). This finding is in 
line with data of Cardeno and coworkers [20] who demonstrated that 
oleuropein and hydroxytyrosol have anticancer activity on HT-29 human colon 
cancer cells only at concentrations higher than 400 and 200 µM, respectively. 
The higher anticancer activity of the whole extract compared to the purified 
polyphenol could be potentially attributed to a synergistic action among the 
various components of the extract. Based on these preliminary results, the 
whole phenolic extract was used for the subsequent experiments instead of the 
isolated chemical compounds. We also examined the effect of EVOO-E subtoxic 
doses  on the clonogenic survival of  T24 and 5637 cells. This  assay determines 
the ability of a cell to proliferate indefinitely, retaining its reproductive ability 
to form a large colony or a clone. Interestingly, the data (Figure 9) showed a 
significative  decrease in the ability of both  cell lines to form colonies starting  
at a dose of 5 μg/mL with a marked inhibition of clonogenic activity at 10 
μg/mL. 
4.6 EVOOE blocks the cell cycle progression at G2/M stage 
To better understand the mechanism underlying cell growth suppression by 
EVOOE, the cell cycle progression was investigated. T24 and 5637  cells were 
treated with increasing doses of EVOO-E, and cell cycle distribution analysis 
was then performed after 24 hours of exposure. As shown in Figure 10, G2/M 
population of EVOOE-treated T24 cells  increased , from 11.1% of the control  to 
27.1% at EVOO-E doses of 20 and 40 μg/ml respectively.  The treatment also 
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induced a marked decrease of G0/G1 population in a dose dependent manner 
with a subsequent increase of sub-G1 particles. This result revealed that 
EVOOE treatment caused marked accumulation of a G2/M population in T24 
cells that lead to an accumulation of sub G1 fraction probably indicating and 
induction of apoptosis. The cell cycle analysis of 5637 after EVOOE treatment 
revealed a similar behavior to what observed for T24 with a bigger increase of 
G2/M population at 40 μg/ml ( 27.1% of T24 versus 44 %of 5637) and the 
absence of sub-G1 fraction. The data obtained from cell cycle analysis show a 
similar mechanism of action of EVOO-E in fact both the cell lines tested  were 
subject to growth arrest  prior to mitosis despite their different mutational 
status. An hypothesis we made to explain this similar response to the 
polyphenols extract action is that EVOO-E can interfere with the cytoskeleton 
remodeling and the subsequent mitotic process. During all of our experiments 
we always notice a change in cell morphology. After the treatment with greater 
concentration of EVOOE (20-40 μg/ml) the cells acquire a rounded 
morphology. In order to verify the alteration of the cytoskeleton we performed 
Immuno fluorescence experiments using Phalloidin (that bind to F-Actin) and 
an antibody against β-Tubulin . As it can be clearly visible  from the Figure 11 
the treatment induce a change in cell morphology with a marked variation of 
cytoskeleton network arrangement. This observation is in line with the findings 
of Hamdi et al[88] that demonstrated how Oleuropein treatment  disrupts the 
organization of actin filaments altering cancer cells shape and their ability to 
proliferate. 
44 
 
4.7 EVOOE induce apoptosis only in T24  
Despite  the cell cycle is  blocked  in the G2/M phase in both the cell lines, cell 
cycle analysis  experiment revealed only in T24 cell, an accumulation of 
particles (sub G1) with a small content of DNA that usually indicate 
apoptosis(Figure 12). In order to confirm the above hypothesis we performed 
Western blot analysis of PARP and pro-Caspase 3-9.  EVOO-E was found to 
induce apoptotic cell death only in  T24 cells in a dose dependent manner. 
Therefore apoptosis was observed at 24 h, as indicated by the cleavage  of 
PARP. Proteolytic cleavage of specific proteins such as PARP has been shown 
to occur in cells exposed to a number of apoptotic stimuli[89-91]. Western blot 
analysis of the cleavage of PARP showed a decrease in the full-size Mw 116,000 
fragment and an increase in the cleaved fragment within 24 h after the bladder 
tumor cells were treated with 20 μg/ml or 40 μg/ml of EVOOE (Figure 13). 
Western blot analysis of procaspase 3 and 9 also showed a marked decrease of 
their protein expression at higher doses of polyphenols extract indeed  cleavage 
that triggers the activation of various enzymes  to initiate apoptotic cell death. 
Conversely to what observed for T24, the treatment  of 5637 cells does not 
induce apoptosis as it is clearly visible from the Figure 13. This different 
behavior  between the two cell lines tested, in response to EVOO-E treatment, 
can be explained by different reasons such as different mutational status in key 
genes involved in  cell proliferation regulation(Table 5). The induction of 
programmed cell  death only in T24 can also explain the different susceptibility 
to the cytotoxic action of EVOOE showed in the firsts experiments (figure 3). 
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4.8 Evaluation of cytotoxic effect of conventional chemoterapics in 
association with EVOOE. 
In the last part of this study we wanted to evaluate if the simultaneous 
treatment of T24 cells with commonly used chemotherapics and sub toxic doses 
of EVOOE can improve the cytotoxic properties of the drugs. We chose to use 
for all the experiments a concentration of  EVOOE of 10 μg/ml which is not 
toxic, as previously described (see Figure 4) but can strongly affect gene 
expression (Figure 6). Prior to each experiments we performed cytotoxicity 
assay using only the chemoterapics in order to asses the IC50 (data not shown)  
and the right doses of drugs to use in the next experiments.   
4.8.1 EVOOE does not alter Etoposide cytotoxicity 
Etoposide is a semisynthetic derivative of podophyllotoxin, a substance 
extracted from the mandrake root Podophyllum peltatum. Having potent 
antineoplastic properties, etoposide binds to, and inhibits, topoisomerase II and 
impairs its function in ligating cleaved DNA molecules, resulting in the 
accumulation of single- or double-strand DNA breaks, the inhibition of DNA 
replication and transcription, and apoptotic cell death. Etoposide acts primarily 
in the G2 and S phases of the cell cycle. Etoposide is approved by the Food and 
Drug Administration (FDA) to treat refractory testicular cancer and small cell 
lung cancer. It has also been useful for other types of cancer, including non-
small cell lung cancer, leukemia (acute myelocytic leukemia ),uterine 
carcinoma, myeloblastoma,  mycosis fungoides ,  neuroblastoma , and prostate 
cancer. After the determination of drugs  IC50, we treated for 48 hours, T24  
cells with different doses of Etoposide in association with  10 μg/ml of EVOOE. 
As it is clearly visible from the Figure 14 the cotreatment does not improve the 
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cytotoxicity of the drug and there with no significant difference between the 
concentration tested.  
4.8.2 EVOOE decreases Mitomycin C toxicity 
 
Mitomycin is a methylazirinopyrroloindoledione antineoplastic antibiotic 
isolated from the bacterium Streptomyces caespitosus and other Streptomyces 
bacterial species. Mitomycin C generates oxygen radicals, alkylates DNA, and 
produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. 
Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein 
synthesis at high concentrations. In the chemotherapy of bladder cancer, 
togheter with the baciluss of Calmette Guerin, this drug is often used[92]. The 
treatment consistS in an intravesical instillation of a 1 mg/mL solution  of 
Mitomycin retained for two hours inside the bladder. To evaluate the effect on 
cell viability of the simultaneous exposure to the drug and EVOO-E we treated 
for 48 hours T24 cells with different doses of  Mitomycin with and without  10 
μg/ml of phenolic extract. The data showed in Figure 14 panel b demonstrated 
that, at any concentration tested, the simultaneous treatment reduced the drug 
cytotoxicity. At a drug concentration of 100 μg/ml the cell viability increased 
from about 15% when exposed to Mitomycin alone to 50% of the cotreatment, 
and similar behavior was observed at all of the concentration tested. The data 
showed show that EVOO-E reduced Mitomycin antiproliferative ability. These 
results are surprising only in part, indeed it is know that one of the Mitomycin 
C mechanism of action is a ROS-dependent activation of apoptotic cell 
death[93], probably the antioxidant properties of EVOOE can interfere with the 
ROS production induced by the drug, thus reducing its citoxicity. Even if this is 
the first study about the interaction of EVOO phenols and Mitomycin there are 
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many reports [94-96] that show how different phenolic molecules extracted 
from various biological matrix can reduce Mitomycin  genotoxic damage due to 
their antioxidant activity. 
4.8.3 EVOOE strongly increases Paclitaxel induced apoptosis. 
Paclitaxel is a mitotic inhibitor isolated from the bark of the Pacific yew tree, 
Taxus brevifolia and named it taxol. Later it was discovered that endophytic 
fungi in the bark synthesize paclitaxel that belongs to the family of taxoid wich 
are diterpenoids with a structure based on the taxane skeleton. This  
antineoplastic agent is indicated for the treatment of advanced carcinoma of the 
ovary, and other various cancers including bladder cancer. Paclitaxel is a 
antimicrotubule agent that promotes the assembly of microtubules from tubulin 
dimers and stabilizes microtubules by preventing depolymerization[97]. This 
stability results in the inhibition of the normal dynamic reorganization of the 
microtubule network that is essential for basic vital process  and cell replication. 
Paclitaxel effect is due to  its ability to interfere with the normal function of 
microtubule growth. Whereas drugs like colchicine cause the depolymerization 
of microtubules in vivo, paclitaxel arrests their function by having the opposite 
effect; it hyper-stabilizes their structure destroying the cytoskeleton flexibility. 
Specifically, paclitaxel binds to the β subunit of tubulin. Tubulin is the "building 
block" of microtubules, and the binding of paclitaxel locks these building blocks 
in place. The resulting microtubule/paclitaxel complex does not have the 
ability to disassemble. 
 To perform our experiments, first we determined the drug dose response curve 
and then we treated we treated for 48 hours T24 cells with three different 
concentrations of Paclitaxel alone or in association with  10 μg/mL of EVOOE. 
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The obtained data are show in Figure 14 panel C. Interestingly, at every tested 
concentration the addition of EVOO-E strongly increases the drug cytotoxicity. 
When we treated the cells with 5 nM of Paclitaxel the cell viability decreased 
from 75% of the drug alone to about 25% of the association treatment, and 
similar response was observed at 20 and 100 nM. Moreover the data analysis 
showed that exposure to 100 nM  of Paclitaxel exert the same cytotoxicity of 5 
nM of the same drug if used in association with EVOOE. Collectively the data 
demonstrates, that combination of EVOOE and paclitaxel possesses a higher 
antiproliferative activity in vitro compared with each of them alone. In order to 
evaluate the mechanism behind the increase cell death we performed western 
blot to asses PARP cleavage after the same treatments of the above experiment. 
As it is clearly visible from the Figure 15, the simultaneous treatment of 
Paclitaxel and EVOOE strongly increase the apoptotic cell death at every of the 
tested concentration, with a marked accumulation of  the 85 kDa  cleaved 
fragment of PARP. To our knowledge this the first report that show how EVOO 
phenols drastically improve the activity  of Paclitaxel and more experiments are 
needed to clarify the mechanism behind this synergism. One of the hypothesis 
we made, that need to be investigated, is the involvement of MDR protein such 
as P-Glycoprotein in the chemosensitization induced by EVOOE. There are 
many reports that show how different polyphenol molecules (catechin from 
green tea or tannin from grape) exert their chemosensitizing activity reverting 
MDR expression[98]. Another interesting evidence supporting our hypothesis is 
the recent work of Xia et al[99] demonstrating that aberrant expression of the 
MDR1-encoded P-glycoprotein (P-gp) is associated with alteration in Wnt 
signaling. In this work the authors show how β-catenin knocking down f 
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completely  abrogates MDR1 transcription and expression resulting in a 
complete reversal of P-gp-dependent efflux function. The above findings are of 
great interest because in our EMT gene expression experiment we also found a 
strong downregulation of β-catenin (Figure 6) therefore this can be a good 
starting point for further experiments. 
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5 Conclusion 
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It is widely known that the polyphenols contained in various foods exert 
beneficial effects on health due to their antioxidant, anticancer and anti-
inflammatory properties [100]. There is a wide body of literature which studies 
the effect of single polyphenols such as TY, EGCG, quercetin, resveratrol, etc., 
whereas less efforts have been devoted to the elucidation of complex matrices 
extracted from foods. In recent years our group started to study the biological 
effects of complex matrices extracted from different foods rich in polyphenols 
and antioxidants [101]. In the present work, our first aim was to evaluate the 
effects of total polyphenols extracted from a locally produced EVOO against 
cancer cells ability to spread. The anticancer effect of olive oil polyphenols is 
well known, however, for the first time we demonstrated that EVOO-E exerts 
an antiproliferative effect on bladder cancer cells in vitro and furthermore we 
demonstrated that olive oil polyphenols are able to inhibit the metastatic 
potential of T24 by inhibiting cell migration and invasion through a 
downregulation of MMP-2 expression. Also, it is of great interest to highlight 
that the cytotoxic effects observed were specific for T24 cells, a cell line widely 
used as a model for bladder carcinogenesis [102-104] and known to be highly 
invasive and aggressive, whereas no effect was evidenced in normal human 
fibroblasts. 
It is well known that tumor metastasis occurs in many steps including vessel 
formation, cell attachment, adhesion, invasion, migration and proliferation, and 
these events are regulated by extremely complex mechanisms. Our findings 
indicate that EVOO-E is able to drastically reduce in vitro invasion and 
migration of T24 bladder cancer cells interfering with EMT gene expression. 
Interestingly we found that the exposure to low concentration of EVOO-E, easy 
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to achieve in vivo, can revert the epithelial to mesenchymal transition in our 
cellular model, giving a less invasive phenotype mainly targeting 
metalloproteinases. Numerous reports have shown that the inhibition of MMPs 
expression and/or enzymatic activities can be used as an early target for 
preventing metastasis[105, 106]. MMP-2 is involved in the invasive metastatic 
potential of tumor cells not only through the degradation of ECM [107] but also 
by the regulation of cell motility by interacting with integrines and guiding the 
direction of cell migration [108]. Our results show that at subtoxic doses, 
EVOOE inhibits MMP-2 activity and subsequently affects the process of 
migration and invasion. Notably, both phenomena can be attributed to the 
lower activity of MMP-2. Indeed, gene expression analysis reveals a significant 
decrease of MMP-2 expression and this result is in good agreement with what 
observed for the enzymatic activity analysis. 
We notice and upregulation of TIMP-1 and TIMP-2 which are endogenous 
tissue inhibitors of metalloproteinases. TIMP-1 has been shown to regulate 
MMP-2 activity and numerous evidences have indicated a correlation between 
elevated TIMP-1 levels and diminished MMP-2 activity and cell 
invasiveness[84-86]. These inhibitory effects of EVOO-E on T24 cells are not due 
to the cytotoxic effect of polyphenols since the viability of these cancer cells was 
not affected in the range of concentration tested (Figure 4). We also performed 
qRT-PCR on  HT1197 transitional bladder cell line which derives from a grade 4 
transitional cell carcinoma of the bladder. We observed an effect strictly similar 
to what evidenced in T24 cells, i.e. a strong down-regulation of MMP-2 
expression and a negligible effect on MMP-9 (data not shown). These data 
indicate that EVOOE exerts its effects on MMP-2 expression independently of 
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the cell line used. Furthermore these data indicate that EVOOE mechanism of 
action is in part due to a regulation of gene expression, particularly for those 
proteins involved in migration and invasion. This findings are well supported 
by the gene expression analysis of EMT related protein that show how the 
EVOO-E treatment revert this phenotypical change that is a hallmark of 
different type of cancer cells. In the second part of this study we clarify how the 
olive oil phenolics exert their antiproliferative activity inducing a block of the 
cell cycle progression at G2/M stage probably due to interaction with the 
cytoskeleton. Interestingly we found a different cellular response in EVOO-E 
ability to induce cell death. We found the activation of apoptosis only in T24 
and therefore an improvement of cell toxicity. This finding is not surprising to 
our point of view because of  the different biology of the cell lines  tested, but 
highlights the need of more and different experimental models to better 
understand olive oil phenols mechanism of action. In the last section of this 
work we evaluated the ability of low concentration of EVOO-E to improve the 
activity of different chemotherapics used in the common clinical practice. It is of 
great interest to underline that the current adjuvant therapy in the management 
of BCa consist in bladder instillation of alchilant agents [92] that otherwise 
could exert unfavourable effects [109]. Usually from an analytical point of view,  
different statistical analyses could be  performed to test for synergistic, additive, 
or sub-additive interactions of combined  treatments. These methods include  
isobologram analyses[110], mean inactivation dose[111] or the median effect  
principle[112],  all of them require  the generation of big data amount using a 
broad  range of concentrations of different treatments.  In this study we were 
able to use a simple approach based on the comparison of viability since one of 
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the two treatments given in co-association is always not toxic (EVOO-E). As 
expected we obtained different results based on the drug tested. Our data 
demonstrated that simultaneous treatment with Mitomycin and EVOO-E 
markedly decrease the cytotoxicity of the drug probably due to the antoxidant 
activity of the phenol molecules contained in the extract. It is well known that 
many molecules of vegetal origin can interfere with drug therapy. For example 
the interaction between garlic and Coumadin is well documented[113], but to 
our knowledge there are no data about customized  diet plan to take before and 
after Mytomycin treatment even if there are controversial data about the role of 
antioxidants supplements during chemotherapy[63-65]. Probably, a good intake 
of EVOO-E after the chemotherapy can be helpful in two different manner 
because it can counteract the toxic residual of alchilating agent, exerting at the 
same time, the above mentioned anticancer properties. Conversely to what 
observed for Mitomycin, the addition of EVOO-E to the Paclitaxel treatment 
lead to a strong  increase of the drug toxicity with a marked induction of 
apoptotic cell death. These data are of big interest because the dose of EVOO-E 
used for this experiment is not toxic to the cells themselves, and not induce the 
cytoskeletal alteration observed at higher concentration. In our opinion the 
cytotoxicity enhancing  of  Paclitaxel maybe due the observed alternation of 
gene expression (occuring at low doses of phenolic extract) that chemosensitize 
the cells by altering the signaling pathways involved in cell proliferation. 
Collectively our findings suggest that the potential adjuvant properties of 
EVOO phenols are related to the class of drugs used according to previously 
published data that point out how the adjunct of high doses of antioxidant to 
chemotherapy does not always  improve the pharmacological treatments[114]. 
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It is important to highlight  that even if the mechanism of action of many 
chemotherapics and also radiotherapy is based in part on the production of free 
radicals[64, 65]  (in that case the intake of antioxidant is not suitable) there are 
also cytostatic drugs that do not work through oxidative stress mechanism like 
paclitaxel, vinca alkaloids, anthracycline and many others that can be improved 
by the use of antioxidant rich supplements[63]. The results obtained in this 
work suggest that EVOO-E may have efficacy, if delivered directly to the 
bladder, either alone or in combination with specific therapeutic agents for the 
treatment of bladder cancer. Moreover, the experimental evidence collected  
support the growing body of epidemiological data which link olive oil 
consumption to lower incidence of  BCa confirming the bioactivity of natural 
compounds and their potential use in cancer therapy. Collectively, EVOO-E has 
multiple anti-metastatic effects and has the potential to be developed as a non-
toxic adjuvant for bladder cancer treatment.  
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Fatty acid Description
Oleic Acid (C18:1) monounsaturated omega-9 fatty acid. It makes up 55 to 83% of olive oil.
Linoleic Acid (C18:2)  polyunsaturated omega-6 fatty acid that makes up about 3.5 to 21% of olive oil
Palmitic Acid (C16:0) saturated fatty acid that makes up 7.5 to 20% of olive oil.
Stearic Acid (C18:0) saturated fatty acid that makes up 0.5 to 5% of olive oil
Linolenic Acid (C18:3)  polyunsaturated omega-3 fatty acid that makes up 0 to 1,5% of olive oil
 
Table 1 Fatty acids composition of a common extra virgin olive oil.  
Polyunsaturated fatty acids (PUFAs) with 18 carbon (C18) atoms such as 
linoleic (18:2 ω-6), and α-linolenic (18:3 ω-3) are known as essential fatty acids 
(EFAs) in human nutrition. These fatty acids, although regarded as an 
indispensable component for cell structure and development and function, 
cannot be synthesized by the human body. The intake of PUFA is necessary 
through diet, and should account for only 6–8% of calories from fat. 
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Figure 1 Biophenols and related compounds identified in olive or olive mill 
waste. 
 Iridoids are monoterpenes (C10) arising from the folding of geraniol (114), 
characterized by a bicyclic fused ring system (six-membered heterocyclic ring 
fused to cyclopentane ring). Secoiridoids are obtained through opening of the 
five-membered ring of iridoids.  
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Figure 2 Forest plot of studies that evaluated the association between olive oil 
intake and cancer development 
 Data are presented as log Odds Ratios and the corresponding 95%CI. The 
highest category of olive oil consumption was associated with lower odds of 
having any type of cancer if compared with the lowest (log odds ratio = -0.41, 
95%CI -0.53, -0.29, Cohran's Q = 47.52, p = 0.0002, I-sq = 62%); Moreover, olive 
oil consumption was associated with lower odds of developing breast cancer 
(logOR = -0,45 95%CI -0.78 to -0.12), and a cancer of the digestive system 
(logOR = -0,36 95%CI -0.50 to -0.21), compared with the lowest intake 
(Psaltopoulou et al.) [115] 
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Reverse:  GCTTGCGAGGGAAGAAGTTG
Forward: CCCCAGACAGGTGATCTTGAC
Reverse:  AGGTTGGATACATCACTGCATTA
Forward: CGCTGGGCTTAGATCATTCC
Reverse:  GGCTTGGAACCCTTTATACATC
Forward:GGGACACCAGAAGTCAACCA
Reverse:  TCACAGCCAGTACCTGGTCGCA
Forward:TCTCAGGCCCTTTGAACATC
Reverse:  CCATCCAATCGGTAGTAGCG
Forward: TCTCAGGCCCTTTGAACATC
Reverse:  TCTTTGACCACCGCTCTCCT 
Forward: AGTGCCAACTGGACCATTCA
Reverse:  TGCAGATCGGACCGGATACT
Forward: TGGGAATCCGACGAATGG
Reverse:  ACGCAAAGGTGCATGATTTG
Forward: CCCACTGGCCTCTGATAAAGG
MMP2
MMP9
TIMP1
TIMP2
18S
E-Caderin
N-Caderin
β-Catenin
 
 
Table 2  List of primers used in qRT-PCR experiments and their sequences 
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Figure 3 High-performance liquid chromatograms of the phenolic fraction of  
a representative virgin olive oil extract. 
 Elution was monitored at 280 nm and peak identification was obtained by 
comparing retention times and spectral characteristics with those of authentic 
standards. Peaks corresponded to (1) hydroxytyrosol, (2) tyrosol, (3) vanillic 
acid, (4) vanillin, (5) p-coumaric acid, (6) ferulic acid, (7) dialdehydic form of 
elenolic acid linked to hydroxytyrosol (3,4-DHPEA-EDA), (8) dialdehydic form 
of elenolic acid linked to tyrosol (p-HPEA-EDA), and (9) pinoresinol. (Coccia et 
al). [116]  
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Peak 
number
Compound name
1 Hydroxytyrosol       
2 Tyrosol                  
3 Vanillic Acid            
4 Vanillin                  
5 P-coumaric Acid,  
6 Ferulic Acid           
(3,4-DHPEA-EDA)  
Dialdehydic Form Of Elenolic Acid Linked To Hydroxytyrosol 
(P-hpea-eda)        
Dialdehydic Form Of Elenolic Acid Linked To Tyrosol 
9 Pinoresinol          
Other 8,6  ±  3 
Average composition of EVOO-E across 30 samples
4,2 ±  0,5  
4,8 ±  0,5 
19,9  ±  2 
7
8 16,7 ±  2 
26,3   ±  2 
Area  %
7,5 ±  2  
4,2 ±  0,5 
4  ±  0,3 
3,8  ±  0,5 
 
 
Table 3  Average composition of EVOO phenol extract.  
 Chromatographic analyses  was performed on 30 sample of EVOO extract 
obtained from different olive oil lots. The comparison between the peak area 
revealed no major differences in phenolic content of the various lots, which 
were characterized by a large amount of secoiridoids ( 7,8) and  lignans such as 
pinoresinol
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Figure 4 Effects of EVOO-E treatment on cell viability, adhesion and motility. 
 After 24 hours of exposure to various concentration of EVOO-E (0-100 µg/ml). 
EVOO-E significantly inhibits the viability of T24 bladder cancer cells. The 
effect on  cell adhesion, migration and invasion was evaluated at subtoxic 
concentration of EVOO-E after 24 hours of exposure. As shown in the figure the 
cell adhesion assay indicates that there are no significant differences between 
treated cells when compared to the control both in T24 and in fibroblasts. As 
regards cell migration and invasion, data indicate that fibroblasts were not 
inhibited by the phenolic extract at the tested concentrations,while the  phenolic 
extract had a significant inhibitory effect on T24 cell motility. After 24 hours of 
treatment with the same doses of EVOO-E used above, the percent of migrated 
cells decrease from 70 ± 2% to 10 ± 3%, respectively. Furthermore, the 
penetration of the Matrigel-coated filter by T24 cells (invasion assay) was 
substantially inhibited in the presence of EVOO-E in a dose dependent 
manner.The percent of invading cells after exposure to EVOO-E concentration 
ranging between 2.5 to 10 μg/mL drastically decrease from 53 ± 2% to 12 ± 1% 
respectively (Fig.3C).The data are presented as means ±SD. *** P<0.001 vs. 
control (Coccia et al)[116].  
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Figure 5 Invasion index 
 To evaluate the differences between migration and invasion on T24 bladder 
cells  we compare the data of this two assays obtained in the same experimental 
condition. We assessed invasive potential by calculating an invasion index, 
which is the ratio of percentage invasion through the Matrigel-coated filters 
relative to migration through the uncoated filters of test cells over that of the 
control counterparts. The evaluation of the invasion index, whose value is 
significantly lower than 1, indicates that the inhibition of invasion is not only 
due to an altered cell motility, but also due to a limited ability to degrade 
ECM.The data are presented as means ±SD. *** P<0.001  T24 migrated cells  vs. 
T24 invaded cells 
 
65 
 
  
 
  
 
                
  
Author 
Number 
of 
patient  
Sample 
source 
Detection method 
Conclusion 
proposed 
  
  
Margulies  
et al[117] 
55 Urine ELISA, Western blot 
MMP-2 levels 
increased in 
cancer 
       
  
 Gohji et 
al[118] 
233 Serum ELISA 
High MMP2 in 
advanced disease   
  
 Hamasaki 
et al [86] 
  T24 cell line RT-PCR, EIA 
MMP2/TIMP2 
imbalance 
suggest 
progression   
  
 
Kanayama 
et al[119] 
41 Frozen tissue RT-PCR 
MMP-2 & TIMP-2 
associated with 
stage   
  
 
Furukawa 
et al[120] 
  
UCT1 and 2 
lines 
RT-PCR  
MMP-2 higher in 
invasive UCT-1  
line implants   
  
 Kanda et 
al[121] 
61 Frozen tissue Zymography 
MMP-2 
associated with 
grade,stage and 
result   
  
 Vasala et 
al [122] 
54 Paraffin/tissue Immunoistochemistry 
MMP-2 
associated with 
stage and worse 
survival   
  
Sumi et 
al[123] 
20 Paraffin/tissue Immunoistochemistry 
MMP-2 
associated with 
grade,stage and 
result   
  
          
  
Table 4 Scentific data about the MMP2 and TIMP2 association to aggressive behaviour of bladder 
cancer
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Figure 6 Quantitative real-time PCR of  EMT  related genes 
 The data obtained show a marked decrease in the gene expression  level of N-
Cadherin, MMP2, Vimentin and β-Catenin  with a subsequent up-regulation of 
E-Cadherin, TIMP1 and TIMP2  after the treatment with EVOO-E. The data are 
presented as means ±SD. 
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Figure 7 Gel zymography analysis of MMP-2 and MMP-9  activity in serum 
free conditioned medium after exposure to EVOO-E. 
 To achieve MMPs positive controls were used  commercially available 
recombinant MMP-2  (72 kDa) and MMP-9 (92 kDa). The densitometric analysis  
show a significantly reduction  (P<0.001) of enzymatic MMP-2 activity in a dose 
dependent manner. The data are presented as means ±SD. *** P<0.001 vs. 
control. (Coccia et al). 
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ATCC® No. Name Primary Site Tissue Tumor Source Histology Mutant Gene Zygosity
HRAS homozygous
TP53 homozygous
TP53 heterozygous
urinary bladder primary carcinoma RB1 homozygous
TP53 homozygous
NRAS heterozygous
PIK3CA heterozygous
 T-24 HTB-4™
urinary bladder primary carcinoma 
urinary bladder primary carcinoma 
HTB-9™ 5637
CRL-1473™  HT-1197 
 
Table 5  Gene mutation status of bladder cancer cell lines used in the present 
work 
Although some significant heterogeneity and complexity between these cell 
lines their genomic profiles exhibited a similar pattern to Urinary Bladder 
cancer. 5637 well represent the E2F3/RB1 pathway due to amplification of 
6p22.3, concomitant with loss of one copy of RB1 and mutation of the 
remaining copy. The T24 belongs to the alternative pathway 
of FGFR3/CCND1 by presenting mutated HRAS and over-
represented CCND1. These cell lines cover the more frequent subtypes of 
Bladder cancer and are reliable models that can be used, as a group, in 
preclinical studies[124]. The HT1197  where chose for their high degree of 
epithelial differentiation. 
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Figure 8  EVOO-E affect cells viability in a dose dependent manner  
Panel A show the different susceptibility to polyphenols extract among the 
tested cells. T24  were the most affected by the cytotoxic action of EVOO-E with 
an  IC50 of 32 ± 3 µg/mL  while the 5637 retain an IC50 of 55 ± 3 µg/mL. 
HT1197 were only slightly affected at the highest concentration of phenolic 
extract tested. The comparison between dose response curve obtained from 
three selected component of the phenolic mixture versus the whole extract 
(EVOO-E), is  shown in panel B. As expected, despite identification of several 
active chemical compounds in EVOO-E, none of the isolated polyphenols 
demonstrated a biological activity higher than the whole oil extract. 
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Figure 9  Clonogenical survival assay 
After 14 days of exposure to low doses of EVOO-E the colony forming ability of 
both the cell lines tested markedly decrease. In particular T24 were the most 
affected cells by the inhibitory action of phenolic extract starting   at a dose of 5 
ug/mL with a marked inhibition of clonogenic activity at 10 ug/mL. 
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Figure 10 EVOO-E blocks the cell cycle progression at G2/M stage 
Cell growth suppression by EVOO-E, was investigated by analyzing the cell 
cycle progression. T24 and 5637  cells were treated with increasing doses of 
EVOO-E, and cell cycle distribution analysis was then performed after 24 hours 
of exposure. G2/M population of EVOO-E-treated T24 cells was increased , 
from 11.1% of the control  to 27.1% at 20 and 40 μg/ml respectively.  The 
treatment also induced a marked decrease of G0/G1 population in a dose 
dependent manner. The cell cycle analysis of 5637 after EVOO-E treatment 
revealed a similar behavior to what observed for T24 with a bigger increase of 
G2/M population at 40 μg/ml ( 27.1% of T24 versus 44% of 5637. 
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Figure 11  Immunofluorescent staining of F-actin and β-Tubulin.  
Immunofluorescence was performed after treating the cells for 24 hours with 
different doses of EVOO-E, for this purpose we used an antibody against β-
Tubulin ( green) and phalloidin marked with TRITC (red) against F-actin. 
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Figure 12 Cell cycle analysis of sub G1 
The cell cycle analysis after EVOO-E treatment  revealed only in T24 cell, and 
accumulation of particles (sub G1) with a small content of DNA that usually 
indicate apoptosis. The percent of sub G1 events in T24  increase from about 6% 
of non treated cells to 28% after the exposure for 24 hours to 40  
 
 
 
 
 
 
 
 
74 
 
 
Figure 13 Western blot analysis of apoptosis related protein 
 Apoptosis was observed at 24 h, as indicated by the degradation of 
PARP.Western blot analysis of the cleavage of PARP showed a decrease in the 
full-size Mr 116,000 fragment and an increase in the Mr 85,000 cleaved fragment 
within 24 h after the bladder tumor cells were treated with 20 μg/ml or 40 
μg/ml of EVOO-E. Western blot analysis of procaspase 3-9 also showed a 
marked diminished expression consistent with the apoptosis induction. 
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Figure 14 Evaluation of cytotoxic effect of conventional chemotherapics in 
association with EVOO-E. 
 The data  show the viability after  the simultaneous treatment of T24 cells with 
commonly used chemotherapics and EVOO-E. We choose to use for all the 
experiments a concentration of  EVOO-E of 10 μg/ml which is non toxic ( white 
bar).
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Figure 15  EVOO-E strongly increases Paclitaxel induced apoptosis. 
The  simultaneous treatment of Paclitaxel and EVOO-E strongly increases the 
apoptotic cell death at any of the tested concentration, with a marked 
accumulation of  the 85 kDa  cleaved fragment of PARP. To our knowledge this 
the first report that show how EVOO phenols drastically improve the activity  
of Paclitaxel. 
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